Pseudohypoaldosteronism associated with hypertrophic cardiomyopathy, hypertension and thrombocytosis due to mutation in the ELAC2 gene: a case report.

IF 1
Luana Carvalho Mendes, Rafael de Oliveira Magalhães, Rodrigo Kelson Pereira Dos Santos, Rogério Santiago Araújo
{"title":"Pseudohypoaldosteronism associated with hypertrophic cardiomyopathy, hypertension and thrombocytosis due to mutation in the ELAC2 gene: a case report.","authors":"Luana Carvalho Mendes,&nbsp;Rafael de Oliveira Magalhães,&nbsp;Rodrigo Kelson Pereira Dos Santos,&nbsp;Rogério Santiago Araújo","doi":"10.1515/jpem-2021-0626","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>PHA1 is a rare heterogeneous disorder featured by changes in renal electrolyte transport due to mineralocorticoid resistance. The aim of the current study is to report the case of a child with 5-year follow-up presenting mutation in the ElaC Ribonuclease Z 2 (ELAC2) gene and clinical-laboratory diagnosis of pseudohypoaldosteronism type 1 (PHA1), as well as atypical clinical manifestations such as thrombocytosis, borderline aldosterone levels, and plasma renin activity.</p><p><strong>Case presentation: </strong>The patient was treated with corticosteroids and salt replenishment. His cardiological condition presented gradual regression and the introduction of new food items in his diet dismissed the need of salt replenishment.</p><p><strong>Conclusions: </strong>This new molecular mechanism should be taken into consideration in differential diagnoses in children with hyperkalemia, hyponatremia, delayed growth, hypertension and hypertrophic cardiomegaly.</p>","PeriodicalId":520684,"journal":{"name":"Journal of pediatric endocrinology & metabolism : JPEM","volume":" ","pages":"1437-1442"},"PeriodicalIF":1.0000,"publicationDate":"2022-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pediatric endocrinology & metabolism : JPEM","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/jpem-2021-0626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/25 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objectives: PHA1 is a rare heterogeneous disorder featured by changes in renal electrolyte transport due to mineralocorticoid resistance. The aim of the current study is to report the case of a child with 5-year follow-up presenting mutation in the ElaC Ribonuclease Z 2 (ELAC2) gene and clinical-laboratory diagnosis of pseudohypoaldosteronism type 1 (PHA1), as well as atypical clinical manifestations such as thrombocytosis, borderline aldosterone levels, and plasma renin activity.

Case presentation: The patient was treated with corticosteroids and salt replenishment. His cardiological condition presented gradual regression and the introduction of new food items in his diet dismissed the need of salt replenishment.

Conclusions: This new molecular mechanism should be taken into consideration in differential diagnoses in children with hyperkalemia, hyponatremia, delayed growth, hypertension and hypertrophic cardiomegaly.

ELAC2基因突变引起的假性醛固酮减少症与肥厚性心肌病、高血压和血小板增多症相关:1例报告
目的:PHA1是一种罕见的异质性疾病,其特征是由于矿物皮质激素抵抗引起肾电解质转运的改变。本研究的目的是报告一名5年随访的儿童病例,该儿童出现ElaC核糖核酸酶z2 (ELAC2)基因突变,临床-实验室诊断为1型假性醛固酮减少症(PHA1),以及非典型临床表现,如血小板增多、醛固酮水平和血浆肾素活性。病例介绍:患者接受糖皮质激素和盐补充治疗。他的心脏状况逐渐好转,饮食中引入新的食物使他不再需要补充盐。结论:在高钾血症、低钠血症、生长迟缓、高血压和肥厚性心肌病患儿的鉴别诊断中应考虑这一新的分子机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信